1062368-24-4 | Quinoline, 4-​[6-​[4-​(1-​piperazinyl)​phenyl]​pyrazolo[1,​5-​a]​pyrimidin-​3-​yl]​-

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$45.00	$32.00
5mg	95%	in stock	$58.00	$40.00
10mg	95%	in stock	$93.00	$65.00
50mg	95%	in stock	$253.00	$177.00
100mg	95%	in stock	$405.00	$283.00
250mg	95%	in stock	$688.00	$481.00

Description

• Catalog Number: AE11254
• Chemical Name: Quinoline, 4-​[6-​[4-​(1-​piperazinyl)​phenyl]​pyrazolo[1,​5-​a]​pyrimidin-​3-​yl]​-
• CAS Number: 1062368-24-4
• Molecular Formula: C25H22N6
• Molecular Weight: 406.48238
• MDL Number: MFCD17169988
• SMILES: N1CCN(CC1)c1ccc(cc1)c1cnc2n(c1)ncc2c1ccnc2c1cccc2

Computed Properties

• Complexity: 587
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 3.3

Upstream Synthesis Route

Quinoline, 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-, is a versatile compound commonly utilized in chemical synthesis processes. This particular derivative of quinoline plays a crucial role in the development of novel pharmaceuticals and agrochemicals due to its unique structural features and reactivity.In chemical synthesis, Quinoline, 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]- can serve as a key building block for the construction of complex molecular structures. Its distinct pyrazolo-pyrimidine core, combined with the substituted quinoline and piperazine moieties, offers chemists a valuable tool for designing and synthesizing biologically active compounds.Researchers and chemists often utilize Quinoline, 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]- in medicinal chemistry projects aimed at developing new therapeutic agents. By incorporating this compound into their synthesis pathways, scientists can explore its potential as a scaffold for drug discovery, targeting various diseases and biological pathways.Moreover, the presence of the piperazine functional group in Quinoline, 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]- enhances its pharmacological properties, making it a valuable intermediate for creating bioactive molecules with enhanced affinity and specificity for biological targets. This compound's versatility and reactivity make it a valuable asset in the realm of chemical synthesis, contributing to the exploration of new therapeutic agents and agrochemicals.

Literature

• Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

  Journal of medicinal chemistry 20141009

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.

  Bioorganic & medicinal chemistry letters 20130601

• ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.

  Cancer research 20130115

• BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.

  PloS one 20130101

• Extraocular ectoderm triggers dorsal retinal fate during optic vesicle evagination in zebrafish.

  Developmental biology 20121101

• Transient downregulation of Bmp signalling induces extra limbs in vertebrates.

  Development (Cambridge, England) 20120701

• Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.

  Molecular cancer research : MCR 20120601

• Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis.

  Arteriosclerosis, thrombosis, and vascular biology 20120301

• Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.

  Arteriosclerosis, thrombosis, and vascular biology 20120201

• The specificities of small molecule inhibitors of the TGFß and BMP pathways.

  Cellular signalling 20111101

• Dorsomorphin stimulates neurite outgrowth in PC12 cells via activation of a protein kinase A-dependent MEK-ERK1/2 signaling pathway.

  Genes to cells : devoted to molecular & cellular mechanisms 20111101

• Application of small organic molecules reveals cooperative TGFβ and BMP regulation of mesothelial cell behaviors.

  ACS chemical biology 20110916

• Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells.

  The international journal of biochemistry & cell biology 20101101

• [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].

  Clinical calcium 20101001

• Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists.

  British journal of pharmacology 20100901

• Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.

  Bioorganic & medicinal chemistry letters 20080801